First-Ever Sickle Cell Gene Therapy Approved For 12 More Countries

A one-time treatment that in trials cured most patients of sickle cell disease is now available in a dozen new health systems, mostly in Europe and the Middle East.

Twelve new countries have approved the first commercial gene therapy for sickle cell disease, a genetic condition that affects roughly six million people worldwide.

The one-time treatment, developed over more than two decades of research, edits a patient's own bone marrow cells to produce healthy hemoglobin, effectively curing the disease in the majority of patients treated in clinical trials.

Access remains the largest question. The treatment's list price is between one and two million dollars per patient. Manufacturers have announced tiered pricing agreements for lower-income countries, though only a handful have yet been finalized.

For patients who have lived their lives managing recurring pain crises, transfusions and shortened life expectancy, the arrival of a curative treatment marks a fundamental shift in what the disease means.

Health economists point out that a one-time cure, however expensive, is often cheaper over a lifetime than decades of standard care. National health services in France, Germany and the UK have all cited that math in approving reimbursement.

Charitable foundations have begun negotiating with manufacturers to establish access programs for sub-Saharan Africa, where the disease burden is highest.

Erfahren Sie mehr Global Health Coverage